Seth P. Lerner

Active 1989–2025

147
Papers
27,683
Citations
86
h-index
139
i10-index

Citations

Citations per year for Seth P. Lerner1945: 1 citations1991: 2 citations1992: 5 citations1993: 2 citations1994: 11 citations1995: 14 citations1996: 7 citations1997: 10 citations1998: 14 citations1999: 19 citations2000: 17 citations2001: 21 citations2002: 23 citations2003: 34 citations2004: 35 citations2005: 50 citations2006: 60 citations2007: 89 citations2008: 81 citations2009: 99 citations2010: 111 citations2011: 112 citations2012: 128 citations2013: 115 citations2014: 146 citations2015: 166 citations2016: 185 citations2017: 213 citations2018: 263 citations2019: 897 citations2020: 996 citations2021: 936 citations2022: 695 citations2023: 537 citations2024: 1,003 citations2025: 473 citations2026: 20 citations1946–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,241 citing papers, 23.3% of this breakdownChina: 1,239 citing papers, 12.9% of this breakdownItaly: 555 citing papers, 5.8% of this breakdownGermany: 534 citing papers, 5.5% of this breakdownUnited Kingdom: 479 citing papers, 5% of this breakdownCanada: 437 citing papers, 4.5% of this breakdownFrance: 396 citing papers, 4.1% of this breakdownSpain: 342 citing papers, 3.6% of this breakdownJapan: 328 citing papers, 3.4% of this breakdownNetherlands: 318 citing papers, 3.3% of this breakdownAustria: 263 citing papers, 2.7% of this breakdownSwitzerland: 199 citing papers, 2.1% of this breakdown
0%23.3%Other 23.8%

Fields

  • Medicine70.5%
  • Biochemistry, Genetics and Molecular Biology23.8%
  • Immunology and Microbiology2.1%
  • Engineering1.1%
  • Computer Science0.6%
  • Neuroscience0.4%
  • Other1.5%

Topics

  • Bladder and Urothelial Cancer Treatments20.4%
  • Urinary and Genital Oncology Studies10.5%
  • Epigenetics and DNA Methylation3.6%
  • Ferroptosis and cancer prognosis3.5%
  • Cancer Immunotherapy and Biomarkers3.2%
  • Cancer Genomics and Diagnostics2%
  • Other56.8%

Coauthors

All papers

Open in search
  1. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mattias Aine, Hikmat Al-Ahmadie, Yves Allory, Joaquim Bellmunt, Isabelle Bernard-Pierrot, Peter C. Black, Mauro A.A. Castro, Keith Syson Chan, Woonyoung Choi, Bogdan Czerniak, Colin P. Dinney, Lars Dyrskjøt, Pontus Eriksson, Jacqueline Fontugne, Ewan A. Gibb, Clarice S. Groeneveld, Arndt Hartmann, Katherine A. Hoadley, Mattias Höglund, Aurélie Kamoun, Jordan Kardos, Jaegil Kim, William Y. Kim, David J. Kwiatkowski, Thierry Lebrét, Seth P. Lerner, Fredrik Liedberg, Núria Malats, David J. McConkey, Qianxing Mo, Thomas Powles, François Radvanyi, Francisco X. Real, Aurélien de Reyniès, A. Gordon Robertson, Arlene O. Siefker‐Radtke, Nanor Sirab, Roland Seiler, Gottfrid Sjödahl, Ann Taber, John N. Weinstein, Alexandre Zlotta - European Urology 2019 cited by 1,360

  2. Comprehensive molecular characterization of urothelial bladder carcinoma Open

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David J. Kwiatkowski, Andrew D. Cherniack, Weiguo Jian, Chandra Sekhar Pedamallu, Richard C. Gibbs, Seth P. Lerner, Kristian Cibulskis, Patricia Garrido Castro, Andrey Sivachenko, Chip Stewart, Michael S. Lawrence, Whitney D. McClenden, Margaret Morgan, Richard C. Gibbs, Scott L. Carter, Chad J. Creighton, Lawrence A. Donehower, Chad J. Creighton, C. Smith, Ami S. Bhatt, Trevor Pugh, Gordon Saksena, Lee Lichtenstein, Michael S. Lawrence, Carrie Sougnez, Kristian Cibulskis, Daniel DiCara, Petar Stojanov, Steven E. Schumacher, Doug Voet, Yingchun Liu, Jaegil Kim, Petar Stojanov, Doug Voet, Pei Lin, Hailei Zhang, Scott L. Carter, Scott Frazer, Michael S. Noble, Daniel DiCara, Lihua Zou, Bernard H. Bochner, Nils Gehlenborg, Ilana R. Garcia-Grossman, David I. Heiman, Juok Cho, Rameen Beroukhim, Dmitry A. Gordenin, David J. Kwiatkowski, Ami S. Bhatt, Andrey Sivachenko, Joonil Jung, Chip Stewart, Andrew D. Cherniack, Samuel S. Freeman, Eric Lander, Michael S. Noble, Tod D. Casasent, David J. Van Den Berg, David J. Kwiatkowski, Nikolaus Schultz, David J. Kwiatkowski, Jianjiong Gao, Anders Jacobsen, B. Arman Aksoy, Ami S. Bhatt, Petar Stojanov, Chandra Sekhar Pedamallu, Rameen Beroukhim, William Lee and 194 more - Nature, Nat. 2014 cited by 3,086

  3. Bladder cancer

    Authors: , , , , , , , , - The Lancet 2016 cited by 1,453

  4. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors

    Authors: , , , , , , , , , , , , , , , , - European Urology 2023 cited by 481

  5. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O’Donnell, David G. Sawutz, Richard Philipson, Ruth Coll, Vikram M. Narayan, F. Peter Treasure, Seppo Ylä‐Herttuala, Nigel Parker, Colin P. Dinney - The Lancet Oncology 2020 cited by 442

  6. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2018 cited by 636

  7. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

    Authors: , , , , , , , , , , , , , - The Journal of Urology 2017 cited by 940

  8. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan L. Wright, Marc Dall’Era, Michiel S. van der Heijden, Peter C. Black - European Urology 2017 cited by 792

  9. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

    Authors: , , , , , , , , , , , , , , - European Urology 2023 cited by 91

  10. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)

    Authors: , , , , , , , , , , , , , , - World Journal of Urology 2016 cited by 472

  11. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

    Authors: , , , , , , , , , , - Nature 2014 cited by 602

  12. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan Bullman, Kristen M. Leraas, Tara M. Lichtenberg, Catherine J. Wu, N. Schultz, Gad Getz, Matthew Meyerson, Gordon B. Mills, David J. McConkey, John N. Weinstein, David J. Kwiatkowski, Seth P. Lerner - Cell 2018 cited by 587

  13. The consensus molecular classification of muscle-invasive bladder cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , The Bladder Cancer Molecular Taxonomy Group - 2018 cited by 152

  14. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence

    Authors: , , , , , , , , , , , , , , , , , , - JAMA 2018 cited by 237

  15. Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

    Authors: , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 166

  16. Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 122

  17. A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

    Authors: , , , , , , , , , , , - The Journal of Urology 2012 cited by 235

  18. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2019 cited by 212

  19. Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease

    Authors: , , , , , , , , , , , , , , - Nature Reviews Urology 2023 cited by 58

  20. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

    Authors: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 cited by 91

  21. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander I. Sankin, Michael A. O’Donnell, David G. Sawutz, Richard Philipson, Nigel Parker, Seppo Ylä‐Herttuala, Dorte Rehm, Jørn S. Jakobsen, Kristian Vinter Juul, Colin P. Dinney - The Journal of Urology 2024 cited by 75

  22. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 53

  23. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314

    Authors: , , , , , , , , , , , , , , , - European Urology Oncology 2023 cited by 30

  24. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , - European Urology 2021 cited by 89